DR. STEPHEN GATELY obtained his Ph.D. from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital. Thereafter he joined the Department of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine as Research Assistant Professor, where his research focused on the identification and development of pharmacologic and endogenous inhibitors of angiogenesis. During this time, Dr. Gately served as a consultant to the Oncology Clinical Research Team at Searle/Monsanto (now Pfizer). In this position, he was responsible for scientific and technical input on clinical trial designs to rapidly assess the utility of antiangiogenic compounds. Additional responsibilities included interacting with discovery scientists to understand drug mechanism of action to aid in the identification of potential biomarkers for early clinical proof of drug activity studies.
He then joined the oncology-focused biopharmaceutical company NeoPharm where he served as Executive Director of Translational Medicine. In this position, Dr. Gately had responsibility for the design and implementation of basic and clinical research studies to enhance the scientific understanding and positioning of existing products and development candidates. Dr. Gately then served as a consultant to Takeda Pharmaceuticals North America, Medical and Scientific Affairs group where he was responsible for the scientific integration of non-clinical, clinical and regulatory data on portfolio compounds for optimal commercial planning. In addition, he was involved in the scientific due diligence for oncology new business development opportunities.
Dr. Gately is currently President and Chief Executive Officer at TD2, and adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine.
SHAUN A. KIRKPATRICK is President at Research Corporation Technologies (RCT) in Tucson, Arizona, and serves on the company’s Board of Directors. Kirkpatrick oversees RCT’s investment portfolio and technology development and licensing activities in therapeutics, life science tools and diagnostics. RCT’s investment and technology portfolio includes over 20 biotechnology companies and some of today’s landmark platforms, pharmaceuticals and diagnostics, including the anticancer drugs cisplatin and carboplatin, the PSA blood test for prostate cancer, the technetium-99-based imaging agents, the Pichia protein expression system, the anticonvulsant drug Vimpat®, and the shingles vaccine Shingrix®. Kirkpatrick received a master’s degree in international economics from the Johns Hopkins University School of Advanced International Studies and a bachelor’s degree in economics and ecology/evolutionary biology from the University of Arizona. Kirkpatrick serves on the boards of several companies in RCT’s venture investment portfolio and is also a board member of the Flinn Foundation in Phoenix, AZ, the Critical Path Institute in Tucson, AZ, and the Thomas R. Brown Foundations, Tucson, AZ.
CHAD SOUVIGNIER is Vice President at Research Corporation Technologies (RCT) where he focuses on the company’s investments in therapeutic platforms and life science tools companies. Dr. Souvignier has nearly 20 years of life sciences venture investing experience. At RCT, he has managed multiple internal programs for the development and commercialization of therapeutic products and platforms and has served as a member of the board for several start-up companies in the RCT portfolio. Previously Dr. Souvignier held roles in business development and international marketing at Guilford Pharmaceuticals. Dr. Souvignier holds an MBA with an emphasis in entrepreneurship and a Ph.D. in Materials Science and Engineering, both from the University of Arizona.